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ABSTRACT 
Objective: The objectives of the present study were to develop and validate a mass compatible ultra-performance liquid chromatography (UPLC) 
method to quantify the impurities in fluticasone nasal spray, and to establish a suitable container-closure system for the formulation. 
Methods: A gradient method was optimized with a flow rate of 0.5 ml/min, detector wavelength-240 nm, run time-25 min and 0.1% Trifluoroacetic 
acid (TFA) in water as solvent A and Methanol as solvent B.  
Results: The developed method was linear over the range of 0.07-1.10 µg/ml for impurity-I, 0.16-2.47 µg/ml for impurity-II, 0.67-10.0 µg/ml for 
impurity-III, and 1.29-19.3 µg/ml for impurity-IV. The limit of quantification (LOQ) and limit of detection (LOD) were established as 0.07 and 0.02 
µg/ml, 0.14 and 0.05 µg/ml, 0.59 and 0.19 µg/ml, 1.06 and 0.35 µg/ml for impurities I-IV respectively. The percent relative standard deviation 
(%RSD) of the replicate analysis for impurities I-IV, was within the acceptance criteria (0.4, 0.2, 0.3, and 0.1% respectively) that proved the 
precision of the method. The accuracy of the method was studied from 50%-150% of test concentration and the results ranged from 100.3% to 
109.4%. The container-closure compatibility study revealed that the solution stored in the glass container system did not generate any additional 
peaks in the chromatogram. 
Conclusion: Hence, the developed method can be employed by quality testing laboratories to quantify impurities in fluticasone propionate nasal 
spray. The study also suggests that glass containers could serve as a compatible system for the storage of fluticasone propionate nasal solution. 
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INTRODUCTION 
Asthma and allergic rhinitis are common respiratory conditions 
associated with airway inflammation. Asthma is characterized by 
airway obstruction, which is at least partially reversible, and airway 
hyper-responsiveness to stimuli such as environmental allergens, 
viral respiratory tract infections, irritants, drugs, exercise, and cold 
air. Common symptoms of allergic rhinitis are nasal congestion, 
rhinorrhea, sneezing, nasal itch, and postnasal drainage [1]. As 
asthma and allergic rhinitis are inflammatory diseases, treatment 
with corticoids is recommended [2].  
Inhaled corticosteroids have, over time, almost entirely replaced 
treatments based on oral corticosteroids, which commonly 
produced major adverse effects. These drugs, because of topical 
application, present a substantially better therapeutic index than 
oral steroids [3]. Also, the treatment of allergic rhinitis has been 
revolutionized by the introduction of topical nasal steroid sprays, 
which are the most common medications prescribed by 
otolaryngology professionals, given that the regular use of these 
sprays reduces nasal obstruction, rhinorrhea, and overall nasal 
symptom scores [4, 5]. 
Fluticasone is a potent, locally active glucocorticoid that has no 
demonstrable systemic side-effects when given by the oral or 
intranasal routes. Glucocorticoids produce several beneficial effects 
on the events involved in allergic inflammation. These include 
inhibition of production of interleukins, inhibition of cellular and 
protein extravasation, inhibition of arachidonic acid generation from 
phospholipids, and a reduction in the release of proteases and other 
enzymes from several cell types [6-8].  
Several investigations have taken place in the quantification of 
fluticasone propionate in bulk drugs as well as drug products using 
liquid chromatography. Buscher et al. developed and validated liquid 
chromatography with tandem mass spectrometry (LC-MS-MS) 
method to quantify budesonide and fluticasone in human sputum 
samples [9]. Paczkowska et al. developed a high-performance liquid 
chromatography (HPLC) method for the simultaneous 
determination of salmeterol xinafoate and fluticasone propionate for 
the quality control of dry powder inhalation products [10]. Byrro 
and his co-workers presented a rapid and sensitive LC-MS-MS 
method to determine fluticasone in human plasma [4]. Akmese et al. 
[11] Angela et al. [12], studied the quantitative assessment of 
fluticasone using liquid chromatography. However, to the best of our 
knowledge, there is no reported mass spectroscopy compatible 
ultra-performance liquid chromatography (UPLC) method available 
to quantify the impurities in a fluticasone propionate nasal spray 
formulation. Although fluticasone is stable when exposed to various 
stress conditions like thermal and acid hydrolysis, it forms several 
unknown impurities in photolytic, oxidative, and alkaline stress 
conditions [13]. Hence, the proposed mass compatible liquid 
chromatography (LC) method will help to quantify the impurities in 
a fluticasone propionate nasal spray.  
MATERIALS AND METHODS 
Chemicals and reagents 
Ultra-pure water obtained from the Milli-Q® water purification 
system (Millipore, USA) was used. Methanol (HPLC grade) and 
Trifluoroacetic acid (TFA) (HPLC grade) used for the studies, were 
procured from Merck, Mumbai, India. Commercially available 
micronized fluticasone propionate nasal sprays were used for 
studies. The Chromatographic column used, Ascentis® Express C18, 
100 × 4.6 mm with 2.7 μm particle size (cat no. # 53827-U), was 
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procured from Sigma Aldrich, Bangalore, India. The centrifuge 
model, Heraeus Megafuge 40, procured from Thermo Fisher 
Scientific, Bangalore, India, was used. Unless stated otherwise, all 
other reagents were of HPLC grade or equivalent, at the minimum.  
Liquid chromatography conditions 
The analyses were performed on the ACQUITY UPLC H-Class 
(Waters, USA) system controlled by Waters EMPOWER 3 software 
and equipped with an autosampler injection system (Waters ACQ-
BSM: 10 µl sample loop), a quaternary solvent manager (Separation 
module), a Photo Diode Array Detector (PDA), and an Ascentis® 
Express C18 column (150 × 4.6 mm, 2.7 μm spherical particles). The 
mobile phase was degassed by filtration through a 0.45 µm Millipore 
membrane filter followed by sonication for 10 min. The injection 
volume was 10 µl and detection was done at 240 nm. The UPLC 
system was operated at 40 °C with the gradient program specified in 
table 1. A mixture of water and methanol (20:80 v/v) was used as a 
diluent.
 
Table 1: LC gradient separation 
Time (min) Mobile phase (%) Flow rate (ml/min) 
A B 
0.0 40 60 0.5 
15.0 20 80 0.5 
17.0 40 60 0.5 
25.0 40 60 0.5 
Mobile phase A: water containing 0.1% TFA, Mobile phase B: Methanol 
 
UPLC-MS-MS conditions 
A Waters Acquity H Glass (Waters, USA) LC system was coupled to a 
Waters Xevo tandem quadrupole mass detector (Waters, USA). 
MassLynx Analyst v.8.0 software was used to control the UPLC-MS-
MS system and collect the mass data. High purity Nitrogen was 
supplied to the mass by a PEAK Scientific generator (PEAK Scientific, 
Scotland). The LC system consisted of an FTN autosampler, a 
quartnery solvent manager, a column oven, and a controller. The 
autosampler was operated at ambient conditions and programmed 
to inject 10 µl of each sample. Gradient separation (table 1) was 
achieved, at a temperature of 40 °C, on an Ascentis® Express column 
(150 × 4.6 mm, 2.7 μm spherical particles). Mobile phase A 
comprised 0.1% TFA in the water, and Mobile phase B comprised of 
Methanol. The autosampler wash contained water-methanol at the 
ratio of 20:80 v/v and was programmed to wash the injection needle 
before and after injection. The liquid chromatogram was recorded at 
240 nm. 
The mass analysis was carried out with an electrospray source and 
the operating conditions were set as follows-scan range: mass 150-
650, desolvation temperature: 350 °C, capillary voltage (kV): 3.50, 
cone voltage (V): 50, and gas flow: 650 L/Hr. Mass parameters were 
optimized by injecting fluticasone propionate standard solution into 
the UPLC-MS-MS system.  
Preparation of solutions 
Preparation of sample solution 
The sample solution containing 55 µg/ml of fluticasone propionate 
was prepared in diluent and analyzed for its impurities as per 
optimized conditions. 
Container-closure compatibility study 
The fluticasone propionate nasal spray solution was filled in 4 ml 
glass vials and high-density polyethylene (HDPE) containers. Both 
samples were subjected to thermal stress of 60 °C for 10 d. They 
were then analyzed for their impurities by UPLC, followed by the 
identification of major peaks by MS-MS. 
Degradation of fluticasone propionate nasal solution 
The fluticasone propionate drug substance was subjected to various 
stress conditions viz., acid hydrolysis, base hydrolysis, water 
hydrolysis, and thermal degradation. These stressed samples were 
analyzed by injecting them into the LC-MS-MS system.  
Preparation of impurities stock solution 
500 µg/ml stock solution of each impurity-fluticasone carboxylic 
acid, fluticasone carbothioic acid, fluticasone carboxylic acid 
propionate, and fluticasone cyclic thioester was prepared in the 
diluent and used to validate the method. 
Validation of fluticasone propionate related substances (RS) 
method by UPLC  
The RS method of fluticasone propionate nasal spray by UPLC was 
validated in terms of specificity, precision, accuracy, linearity, the 
limit of detection (LOD), and limit of quantification (LOQ) according 
to the International Council for Harmonization (ICH) of Technical 
Requirements for Pharmaceuticals for Human Use [14].  
Specificity 
The specificity of the method was studied to ensure that there was 
no interference from the diluent at the retention time of analytes.  
Method precision 
The method precision was assessed by six replicate analyses of 
impurities, spiked in the sample solution. The method is considered 
to be precise if the percent relative standard deviation (% RSD) is 
not more than (NMT) 15.0% for each impurity. 
Accuracy 
The accuracy of an analytical method expresses the nearness 
between the expected value and the value found. It is obtained by 
calculating the % recovery of the analyte recovered. In this case, to 
evaluate the accuracy of the developed method, successive analysis 
(n=3) for three different levels i.e. 50, 100, and 150% of the test 
concentration were performed. The impurities stock solution was 
spiked in the sample solution at 50%, 100%, and 150% of the test 
concentrations. The data obtained from the experiment were 




 × 100 ] to study the recovery and 
validity of the developed method. The mean recovery should be 
within 85-115% to be accepted. 
Linearity  
Linearity is the ability to obtain test results that are directly 
proportional to the concentration of the analyte. Linearity was 
determined by plotting peak area against the concentration of the 
impurity. Here, a 5-point calibration curve is plotted covering from 
LOQ to 150% of the target concentration to calculate the coefficient of 
correlation, slope, intercept, and % bias. The method is considered 
linear if the coefficient of correlation is not less than (NLT) 0.997 and 
% bias at 100% response is NMT 5.0%. The % bias was calculated 
using the formula: [% Bias =
Y intercept
Response for 100%
 × 100 ]. 
Limit of detection and Limit of quantification 
LOD is the lowest concentration in the sample that can be detected 
but not necessarily quantified, under the stated experimental 
conditions. LOQ is the lowest concentration of analyte that can be 
determined with acceptable precision and accuracy. These two 
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parameters were calculated using the formula LOD =
3.3 × SD
S




 where SD-standard deviation of response and S-slope of the 
calibration curve. 
RESULTS  
Container closure compatibility study 
The container-closure compatibility study revealed that the 
chromatogram of the fluticasone propionate nasal solution stored in 
a glass container was in concurrence with the chromatogram of 
freshly prepared solution (fig. 1A, fig. 1B). Conversely, the solution 
stored in the HDPE containers developed an additional impurity at 
the retention time of 5.499 min (fig. 2A). These solutions were 
subjected to UPLC-MS-MS to get the mass of the impurity and it was 
found to be 396.42 (fig. 2B). 
Degradation of fluticasone propionate nasal solution 
No significant degradation was observed in samples subjected to 
acidic, water, and thermal degradation. However, around 22% of 
degradation was observed in the sample subjected to basic 
degradation (fig. 3). This observation is in concurrence with results 
published by Akmese et al. [11]. LC-MS-MS was used to identify the 
degradants in these samples based on their fragmentation pattern 
and mass. The results are presented in table 2 and fig. 3A-3E. 
 
 
Fig. 1A: Chromatogram of freshly prepared fluticasone propionate nasal solution 
 
 
Fig. 1B: Chromatogram of fluticasone propionate nasal solution stored in a glass container 
 
 
Fig. 2A: Chromatogram of fluticasone propionate nasal solution stored in HDPE container 
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Fig. 2B: Mass spectrum of impurity eluting at RT 5.499 min 
 
 
Fig. 3: Chromatogram of basic degradation sample 
 
 
Fig. 3A: Mass spectrum of impurity at RT 5.043 min 
 
 
Fig. 3B: Mass spectrum of impurity at RT 6.379 min 
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Table 2: Impurities of fluticasone propionate nasal solution stored in HDPE container 
RT (min) Impurity [M+H]+ Mass No. 
5.043 I. Fluticasone carboxylic acid 397.28 396.42 
6.379 II. Fluticasone carbothioic acid 470.32 468.55 
7.230 III. Fluticasone carboxylic acid propionate 453.37 452.49 
8.948 IV. Fluticasone impurity (cyclic thioester) 467.31 466.55 
10.198 Fluticasone propionate 501.21 500.57 
 
 
Fig. 3C: Mass spectrum of impurity at RT 7.230 min 
 
 
Fig. 3D: Mass spectrum of impurity at RT 8.948 min 
 
 
Fig. 3E: Mass spectrum of impurity at RT 10.198 min 
 
Validation of fluticasone propionate RS method by UPLC  
Specificity 
The specificity of the method was studied by analyzing the 
diluent and sample spiked with an impurity mixture solution. No 
peak was detected at the retention time of fluticasone and 
impurities which proved the high degree of specificity of the 
method (fig. 4). 
Method precision 
The system suitability was assessed by six replicate analyses of 
sample solution spiked with an impurity mixture solution. The 
acceptance criterion was±15% for the %RSD of the peak area (table 
3 and fig. 5). 
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Fig. 4: Overlay chromatogram of blank and fluticasone propionate nasal solution 
 
Table 3: Method precision 
Test solution Impurity-I Impurity-II Impurity-III Impurity–IV 
1 0.97 2.20 10.60 19.60 
2 0.97 2.21 10.63 19.59 
3 0.97 2.21 10.63 19.60 
4 0.97 2.21 10.66 19.61 
5 0.97 2.21 10.68 19.61 
6 0.98 2.21 10.69 19.62 
Average 0.97 2.21 10.65 19.61 
%RSD 0.4 0.2 0.3 0.1 
 
 
Fig. 5: Overlay chromatograms of method precision 
 
Accuracy 
The accuracy of the method was determined by recovery 
experiments. The recovery studies were carried out in triplicate at 
50%, 100%, and 150% of the target concentration, and the % 
recovery was calculated. The method was considered to be accurate 
if the individual recovery at each level is between 85.0% and 
115.0%. The data revealed that the method is accurate (table 4). 
  
Table 4: Accuracy 
 Level sample Impurity-I Impurity-II Impurity-III Impurity-IV 
50% 1 109.4 105.8 109.0 104.6 
2 109.0 105.3 108.7 104.1 
3 109.9 105.2 108.9 103.9 
100% 1 106.0 102.4 105.6 100.7 
2 106.0 102.4 105.7 100.5 
3 106.2 102.7 105.9 100.7 
150% 1 107.6 102.4 105.8 100.4 
2 108.0 102.6 106.2 100.6 
3 108.3 102.2 106.0 100.3 
 
Linearity  
A linear relationship was observed between the area of the peak 
and the corresponding concentration over LOQ to 150% of the 
test concentration. The coefficient of correlation was found to be 
≥ 0.9998 for all the impurities. And the % bias at 100% was 
found to be-0.5,-0.1,-0.4, and-0.1 for impurity I, II, III, and IV 
respectively (fig. 6A-6D). From the data obtained, it was 
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Fig. 6A: Linearity chart of impurity-I 
 
Fig. 6B: Linearity chart of impurity-II 
 
Fig. 6C: Linearity chart of impurity-III 
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Limit of detection and limit of quantification 
The LOD of impurity I, II, III, and IV were found to be 0.067, 0.141, 
0.587, and 1.058 µg/ml respectively, and the LOQ was calculated as 
0.022, 0.046, 0.194, and 0.349 µg/ml respectively.  
DISCUSSION 
Validation of an analytical method is imperative to assure that the 
developed method will consistently produce the desired result 
meeting its predetermined specifications and quality characteristics 
[15-17]. Although the max of fluticasone propionate was found to 
be 246 nm, considering the absorption values of other impurities, 
240 nm was set as the detection wavelength and column 
temperature was set as 40 °C where all the impurities were well 
separated from each other with the resolution of greater than 2.0. 
The container closure compatibility study demonstrated that the 
glass container system would be a suitable one to store the 
fluticasone propionate nasal solution.  
The sample was found to be stable in acid, water, and thermal 
degradation conditions. Whereas in basic conditions around 22% 
degradation observed. Similar degradation patterns were observed 
in the study conducted by Akmese et al. The developed method was 
found to be specific as no interference was observed at the retention 
time of analytes. The results of precision and accuracy were found to 
be within the limit prescribed in ICH Q2 (R1) guidelines [18]. All four 
impurities are shown a linear relationship between the 
concentration of analyte and areas of the corresponding peaks with 
the co-efficient of correlation value of 0.9998. The LOD and LOQ 
limits were established in this method are by the limit set for 
reporting threshold in ICH guidelines. The developed mass 
compatible UPLC method was successfully adopted to identify and 
quantify the impurities present in the fluticasone propionate nasal 
solution.  
CONCLUSION 
In this study, we have developed and validated a novel, sensitive, 
reproducible, and accurate mass compatible UPLC method, for the 
quantification of impurities in the fluticasone propionate nasal 
spray. Forced degradation study revealed that the solution is 
susceptible to alkaline hydrolysis. The container-closure 
compatibility study demonstrated that the fluticasone propionate 
nasal solution possibly undergoes degradation when the solution is 
stored in the HDPE container and exposed to heat. However, further 
investigation is warranted to better understand the interaction 
between the container-closure system and formulation. Although 
several analytical methods exist for the quantification of fluticasone, 
to the best of our knowledge, this is the first time that a mass 
compatible UPLC method was developed and validated to study the 
impurities in fluticasone nasal solution. Thus, the present study 
might aid in selecting an appropriate container-closure system, and 
to quantify the impurities in fluticasone propionate nasal spray. 
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